BMS-986016

Phase 2Small molecule

Bristol-Myers Squibb

BMS-986016 is one of 7 small molecule programs targeting Immune Checkpoint Inhibition. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Immune Checkpoint InhibitionRecruiting

Immune Checkpoint InhibitionPhase 2

Recruiting

Competition

Competitive Landscape

8 competitors in Immune Checkpoint Inhibition

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

4 2

Yervoy

Bristol-Myers Squibb

Phase 2

3 3

Tecentriq

Roche

Phase 2

1 4

Celebrex

PPhiladelphia Eye Associates

Phase 2

1 5

Tiragolumab

Roche

Phase 2

1 6

BMS-986253

Bristol-Myers Squibb

Phase 2

1 7

BMS-986016

Bristol-Myers Squibb

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2032

Phase 2Recruiting

Immune Checkpoint Inhibition

NCT03026140

Clinical

Trials by Indication[1]

Glioblastoma1 trial

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade

Completed·NNational Institute of Neurological Disorders and Stroke (NINDS)·Phase 1·NCT03493932·21 enrolled

Combination Therapy1 trial

A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT02060188·385 enrolled

Immune Checkpoint Inhibition1 trial

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT03026140·353 enrolled

Relapsed or Refractory B-cell Malignancies1 trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT02061761·106 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for BMS-986016. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BMS-986016 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BMS-986016. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Bristol-Myers Squibb

BMS-986016

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2032

Trials by Indication[1]

Glioblastoma1 trial

Combination Therapy1 trial

Immune Checkpoint Inhibition1 trial

Relapsed or Refractory B-cell Malignancies1 trial

References

Drug Info

Quick Facts

Related News